<span id="b3inl"></span>
  • <i id="b3inl"><meter id="b3inl"></meter></i><rt id="b3inl"><optgroup id="b3inl"><strike id="b3inl"></strike></optgroup></rt>
    <span id="b3inl"><optgroup id="b3inl"></optgroup></span>
    <span id="b3inl"><optgroup id="b3inl"></optgroup></span>

    <span id="b3inl"><optgroup id="b3inl"></optgroup></span>
        Hello! Welcome to the official website of Betta Pharmaceuticals!
        Service Hotline:+86-571-86130357     Add to Favorites | Online Feedback 中文
        Development Path
        2003

        The company was established at No. 2 Tianjiaqiao, Tiyuchang Road, Hangzhou.

        2004

        The company advanced the pre-clinical research of icotinib hydrochloride.

        2005

        The company’s staff celebrated the completion of the pre-clinical studies of icotinib hydrochloride.

        2006

        The company moved to Yuhang Economic and Technological Development Zone and established a manufacturing site.
        Icotinib hydrochloride won the supports from the National Torch Program and the National Science and Technology SME Technology Innovation Fund.

        2007

        Beijing R&D Center was moved for the first time.
        Icotinib hydrochloride received the support from the National 863 Program.

        2008

        Beijing R&D Center celebrated its fifth anniversary.
        The company was recognized as a national high-tech enterprise for the first time.

        2009

        The company held the groundbreaking ceremony of its headquarter in Hangzhou.
        Icotinib hydrochloride won the special project support of National "New Drug Innovation".

        2010

        Manufacturing of icotinib hydrochloride was successfully scaled up in 1,000 liters.
        The clinical study of icotinib hydrochloride was completed clinical research and the industrial manufacturing was initiated.

        2011

        The marketing launch of icotinib hydrochloride results was held in the Great Hall of the People in Beijing and was hailed as a significant milestone in the Chinese healthcare industry.
        Betta Pharmaceuticals academician site was established.

        2012

        The company cooperated with the China Pharmaceutical Promotion Association to launch the Conmana patient assistance program.
        Icotinib hydrochloride was listed in the 2012 Global New Drug R&D Catalogue as the first Chinese innovative drug to be enlisted.

        2013

        The company and Amgen established a joint venture.
        The results of the clinical study of icotinib hydrochloride were published in The Lancet Oncology.

        2014

        The company signed a contract with Xcovery to jointly develop a new generation of ALK inhibitor ensartinib hydrochloride.
        Construction of a new headquarter site was initiated.

        2015

        R&D and commercialization of icotinib hydrochloride won the first prize of 2015 National Scientific and Technological Progress Award.
        The company was appraised as China Overseas Chinese Innovation and Entrepreneurship Site.

        2016

        Betta Pharmaceuticals was listed on the Shenzhen Stock Exchange (300558.SZ).
        Icotinib hydrochloride won China Industrial Award.
        The Chinese Academy of Pharmaceutical Innovation and Industrialization Forum was successfully held at the company's new headquarter.

        2017

        Betta DreamWorks was officially established
        Icotinib hydrochloride was listed on the National Reimbursement Drug List (NRDL).
        The company reached a strategic collaboration with Tyrogenex.

        2018

        Haichuang Park of Betta DreamWorks was officially opened.
        Icotinib hydrochloride was listed on the Essential Drug List (EDL).
        The NDA application of ensartinib hydrochloride was accepted by the National Medical Products Administration (NMPA).

        2019

        Ensartinib hydrochloride was granted the priority review by the Center for Drug Evaluation of NMPA.
        The clinical results of ensartinib hydrochloride were published in The Lancet Respiratory Medicine.
        Icotinib hydrochloride was included in the General Drug Access Catalogue of National Medical Insurance (2019).

        2020

        2021

        The company's first macromolecule biologics product, Bevacizumab, was approved
        Icotinib was approved as postoperative adjuvant therapy for NSCLC.
        Icotinib postoperative adjuvant therapy and Ensartinib were includedthe catalog of medicines covered by national medical insurance system

        2022

        In 2022, CDE approved 4 new indications for Bevacizumab
        Ensartinib Hydrochloride was presented at the CCP’s 20th exhibition on the theme of "Forging Ahead in the New Era"

        2023

        Befotertinib Mesylate and Vorolanib were approved for marketing
        Four products were included the catalog of medicines covered by national medical insurance system

        Award Honor
        • 2023
          Ensartinib hydrochloride won the first prize of Science and Technology Progress Award of Zhejiang Province
          The results of the first-line clinical study of Befotertinib were published in full in The Lancet Respiratory Medicine
          The company won the grand prize of China Biomedicine High Value Patent Competition
          Dr. Lieming Ding, Chairman and CEO, was elected as the 14th CPPCC National Committee
          Dr. Lieming Ding, Chairman and CEO, was elected as the torch bearer for the 19th Asian Games in Hangzhou Torch Relay
          Dr. Lieming Ding, Chairman and CEO, won the title of the role models'of Zhejiang Province
        • 2022
          Ensartinib hydrochloride won the grand prize of Science and Technology of Zhejiang Pharmaceutical Association
          The company was awarded the national advanced unit of professional ethics construction
          The company was awarded the national technological innovation demonstration enterprise
          The company was nominated as the leading enterprise of high-quality development in Zhejiang Province
          Dr. Lieming, Betta’s Chairman and CEO won the title of Zhejiang Good Man
          Yaqin Gao, Betta’s quality engineer, was elected as a representative in the 25th National People’s Ccongress Standing Committee
        • 2021
          The Icotinib EVIDENCE study results were published in the Lancet Respiratory Medicine
          The Bevacizumab study results were published in the Lancet's EClinicalMedicine
          The results of the global first-line eXalt 3 study of Ensartinib were published in JAMA Oncology
          The company won the "National Labor’s Award"
          The company was ranked the top in China's new pharmaceutical innovation force in consecutive years
          The company was ranked the top 100 Pharmaceutical Innovative Enterprises in China
        • 2020
          The results for INCREASE Trial of Icotinib was published in Clinical Cancer Research
          The registered clinical trial of Ensartinib was awarded "Top Ten Original Researches in Chinese Oncology"
          The company was named on the Forbes’ list of Top 50 Most Innovative Enterprises in China The company was identified as "National Enterprise Technology Center"
          The company won “Zhejiang Government Quality Management Innovation Award”
          Dr. Lieming Ding, Chairman and CEO, won "The 3rd Translational Medicine Outstanding Contribution Award"
          · Dr. Lieming Ding, Chairman and CEO, was named "National Advanced Individual in Anti-epidemic" by Chinese Peasants and Workers Democratic Party
        • 2019
          Icotinib hydrochloride was ranked first on the “Innovative Technology” Top 10 list during the National Innovation Week.
          The launch of icotinib hydrochloride in 2011 was listed in New China’s 70 years Healthcare Memorabilia.
          The company was ranked third on the Top 10 Innovative Enterprises in the Asia-Pacific Pharmaceutical Industry.
          The company won the title of Zhejiang Model Company.
          The company was awarded the National Intellectual Property Model Enterprise.
          Dr. Lieming Ding, Chairman and CEO, was named “The Most Beautiful Zhejiang Person of the Year · Zhejiang Pride”.
          Dr. Lieming Ding, Chairman and CEO, was elected Chairman of Zhejiang Pharmaceutical Industry Association.
        • 2018
          The company was approved as the National Postdoctoral Research Site.
          Dr. Lieming Ding, Chairman and CEO, was awarded "Top 10" of Outstanding Overseas Chinese.
          Quality Control Engineer Yaqin Gao won the National Labor Day Medal.
          Dr. Lieming Ding, Chairman and CEO, was named the Zhejiang Non-public Economic Personnel in the New Era of the Chinese Socialist Cause.
          Quality Control Engineer Yaqin Gao won the title of Zhejiang Provincial Model Worker.
        • 2017
          The company was approved as the National Academician Site.
          Dr. Lieming Ding, Chairman and CEO, won the National Innovation Award.
          The company was rated as the “Four Strongest Provinces” leading enterprise.
          Dr. Lieming Ding, Chairman and CEO, won the Zhejiang Innovation Talent Award.
        • 2016
          Icotinib hydrochloride (Conmana) won the highest award in China's industrial field——"China Industrial Award".
          The company was rated as a National Intellectual Property Elite Enterprise.
          The company won the annual Social Responsibility Brand Award on the China Charity Festival.
          The company was approved as the leading Zhejiang Provincial Academician Site.
        • 2015
          The R&D and commercialization of icotinib hydrochloride won the National Prize for Progress in Science and Technology.
          Dr. Lieming Ding, Chairman and CEO, was awarded the first prize of National Science and Technology Progress Award as the lead contributor.
          The company was awarded the China Overseas Chinese Innovation and Entrepreneurship Site.
          The company won the annual Social Responsibility Brand Award on the China Charity Festival.
        • 2014
          The patent for icotinib hydrochloride crystal form won the Gold Prize of China Patent Award.
          Dr. Lieming Ding, Chairman and CEO, was named the National Excellent Professional and Technical Talent.
          Dr. Lieming Ding, Chairman and CEO, was named the National Excellent Science and Technology Worker.
        • 2013
          The company won the Annual Charity Practice Award on the China Charity Festival.
          Dr. Lieming Ding, Chairman and CEO, was appointed as the National Advanced Individual of Returned Overseas Chinese.
        • 2012
          The composition of matter patent of icotinib hydrochloride won the Gold Prize of China Patent Award.
          The company’s R&D team of Ph.D. returnees won the China Overseas Chinese Contribution Award.
          The company was rated as Zhejiang Key Enterprise Research Institute.
        • 2011
          Dr. Lieming Ding, Chairman and CEO,won the Outstanding Contribution Award for the implementation of the National Science Plan of the 11th Five-Year Plan.
        • 2010
          Dr. Lieming Ding, Chairman and CEO,won the China Overseas Chinese Contribution Award (innovative talent).
        • 2009
          The Phase IIb/III clinical trial of the anti-cancer drug EGFR kinase inhibitor – icotinib hydrochloride – for the treatment of non-small cell lung cancer was supported by the National "New Drug Innovation" Science and Technology Initiative.
        • 2008
          The company was recognized as a National High-tech Enterprise for the first time.
        • 2007
          The anti-cancer drug EGFR kinase inhibitor – icotinib hydrochloride – for the treatment of non-small cell lung cancer (NSCLC) was supported by the National High Technology Research and Development Initiative (863 Initiative).
        • 2006
          The development of the anti-cancer drug icotinib hydrochloride was supported by the National Torch Program.
          The R&D of the new anti-cancer drug EGFR kinase inhibitor – BPI-2009H – was supported by the National Science and Technology SME Technology Innovation Fund.
        • 2005
          Dr. Lieming Ding, Chairman and CEO, was named Zhejiang Excellent Entrepreneur.
        主站蜘蛛池模板: eeuss免费天堂影院| 亚洲人成无码www久久久| 精品亚洲A∨无码一区二区三区| j8又粗又长又硬又爽免费视频| 午夜国产羞羞视频免费网站| 欧美日韩亚洲精品| 又黄又爽一线毛片免费观看| 国产亚洲欧美日韩亚洲中文色| 日韩一级免费视频| 精品亚洲成a人在线观看| 日韩一区二区三区免费体验| 亚洲乱码中文字幕在线| 国产精品酒店视频免费看| 亚洲av乱码中文一区二区三区| mm1313亚洲精品国产| www成人免费观看网站| 亚洲成av人在线视| 亚洲一区二区三区免费观看| 亚洲AV综合色区无码二区爱AV| 成年女人毛片免费播放视频m| 久久人午夜亚洲精品无码区| 亚洲人成无码网WWW| 久久这里只精品99re免费| 亚洲午夜在线一区| 国产成人高清精品免费鸭子| 中美日韩在线网免费毛片视频 | 毛片A级毛片免费播放| 亚洲AV噜噜一区二区三区| 亚洲小说区图片区另类春色| 久久国产高潮流白浆免费观看| 亚洲精品福利你懂| 亚洲国产精品嫩草影院久久| 日本视频在线观看永久免费| 亚洲午夜一区二区三区| 亚洲黄黄黄网站在线观看| 91福利免费视频| 免费的黄色网页在线免费观看| 亚洲AV无码不卡在线播放| 四虎影视www四虎免费| baoyu777永久免费视频| 亚洲日韩精品国产一区二区三区|